What is DefiniGEN?
DefiniGEN specializes in the development of induced pluripotent stem cell (iPSC) disease modeling services, offering a sophisticated suite of solutions for metabolic and rare disease research. The company provides high-fidelity human-derived models that are critical for efficacy and toxicology screening, as well as advanced gene editing services. With a focus on conditions such as MASLD and Wilson's Disease, DefiniGEN serves a global clientele of top-tier pharmaceutical companies and research institutions. Their proprietary technology platform, backed by over 13 years of operational experience, enables the creation of scalable and predictive models that significantly enhance the drug discovery pipeline, reducing the reliance on traditional, less accurate animal models.
How much funding has DefiniGEN raised?
DefiniGEN has raised a total of $6.1M across 2 funding rounds:
Series A
$3.8M
Private Equity
$2.3M
Series A (2014): $3.8M with participation from Cambridge Enterprise and 24 Haymarket
Private Equity (2016): $2.3M led by Cambridge Enterprise
Key Investors in DefiniGEN
Cambridge Enterprise
The commercialization arm of the University of Cambridge, focusing on supporting the translation of academic research into impactful commercial ventures.
24 Haymarket
A private network of experienced investors and operators that provides capital and strategic support to high-growth entrepreneurial ventures.
What's next for DefiniGEN?
With the support of major enterprise-level funding, DefiniGEN is well-positioned to scale its operations and expand its portfolio of disease-specific models. The strategic focus moving forward involves deepening its integration into the drug development workflows of global pharmaceutical partners. By enhancing its gene editing capabilities and broadening its library of metabolic disease models, the company aims to accelerate the transition of novel therapeutics from the bench to the clinic. This capital deployment will likely prioritize the optimization of high-throughput screening processes, ensuring that DefiniGEN remains at the forefront of the precision medicine revolution and continues to set the standard for predictive human-derived research tools.
See full DefiniGEN company page
